nach oben

Erschienen in:

01.08.2015 | Original Article

Genetics of serum concentration of IL-6 and TNFα in systemic lupus erythematosus and rheumatoid arthritis: a candidate gene analysis

verfasst von: Joseph F. Solus, Cecilia P. Chung, Annette Oeser, Chun Li, Young Hee Rho, Kevin M. Bradley, Vivian K. Kawai, Jeffrey R. Smith, C. Michael Stein

Erschienen in: Clinical Rheumatology | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Elevated concentrations of inflammatory mediators are characteristic of autoimmune disease accompanied by chronic or recurrent inflammation. We examined the hypothesis that mediators of inflammation known to be elevated in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are associated with genetic polymorphism previously identified in studies of inflammatory disease. Serum interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα) concentrations in patients with SLE (n = 117) or RA (n = 164) and in inflammatory disease-free control subjects (n = 172) were measured by multiplex ELISA. Candidate genes were chosen from studies of autoimmune and inflammatory disease. Genotypes were determined for 345 SNP markers in 75 genes. Association between serum analytes and single alleles was tested by linear regression. Polymorphisms in several genes were associated with IL-6 levels (including IL10, TYK2, and CD40L in SLE and DRB1, NOD2, and CSF1 in RA) or with TNFα levels (including TNFSF4 and CSF2 in SLE and PTPN2, DRB1, and NOD2 in RA). Some associations were shared between disease and control groups or between IL-6 and TNFα within a group. In conclusion, variation in genes implicated in disease pathology is associated with serum IL-6 or TNFα concentration. Some genetic associations are more apparent in healthy controls than in SLE or RA, suggesting dysregulation of the principal mediators of chronic inflammation in disease. Susceptibility genes may affect inflammatory response with variable effect on disease etiology.

Nur mit Berechtigung zugänglich

Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110–2121PubMedCrossRef

Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376(9746):1094–1108PubMedCrossRef

Cho JH, Gregersen PK (2011) Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 365(17):1612–1623PubMedCrossRef

Yap DY, Lai KN (2010) Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010:365083PubMedCentralPubMedCrossRef

McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7(6):429–442PubMedCrossRef

Sanchez E, Nadig A, Richardson BC et al (2011) Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis 70(10):1752–1757PubMedCentralPubMedCrossRef

Zhernakova A, van Diemen CC, Wijmenga C (2009) Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 10(1):43–55PubMedCrossRef

Maier LM, Hafler DA (2009) Autoimmunity risk alleles in costimulation pathways. Immunol Rev 229(1):322–336PubMedCrossRef

Shah T, Zabaneh D, Gaunt T et al (2013) Gene-centric analysis identifies variants associated with interleukin-6 levels and shared pathways with other inflammation markers. Circ Cardiovasc Genet 6(2):163–170PubMedCrossRef

10.

Weinstock M, Grimm I, Dreier J, Knabbe C, Vollmer T (2014) Genetic variants in genes of the inflammatory response in association with infective endocarditis. PLoS One 9(10):e110151PubMedCentralPubMedCrossRef

11.

Vaughn CB, Ochs-Balcom HM, Nie J et al (2013) No association between circulating levels and genetic variants of IL-6 and TNF-alpha and colon adenoma. Gastroenterol Res 6(2)

12.

Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277PubMedCrossRef

13.

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef

14.

Asanuma Y (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2407–2415PubMedCrossRef

15.

Chung CP, Oeser A, Raggi P et al (2005) Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52:3045–3053PubMedCrossRef

16.

Rho YH (2011) Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res (Hoboken) 63:535–541CrossRef

17.

Chung CP, Oeser A, Solus JF et al (2008) Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 58(7):2105–2112PubMedCentralPubMedCrossRef

18.

Rho YH, Solus J, Sokka T et al (2009) Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 60(7):1906–1914PubMedCentralPubMedCrossRef

19.

Rho YH, Chung CP, Oeser A et al (2008) Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol 35(9):1789–1794PubMedCentralPubMed

20.

Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, Van de Putte LB, Van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef

21.

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640PubMedCrossRef

22.

Schnabel RB, Lunetta KL, Larson MG et al (2009) The relation of genetic and environmental factors to systemic inflammatory biomarker concentrations. Circ Cardiovasc Genet 2(3):229–237PubMedCentralPubMedCrossRef

23.

Raychaudhuri S, Sandor C, Stahl EA et al (2012) Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 44(3):291–296PubMedCentralPubMedCrossRef

24.

Cooles FA, Isaacs JD (2011) Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol 23(3):233–240PubMedCrossRef

25.

van der Helm-van Mil AH, Huizinga TW (2008) Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 10(2):205PubMedCentralPubMedCrossRef

26.

du Montcel ST, Michou L, Petit-Teixeira E et al (2005) New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum 52(4):1063–1068PubMedCrossRef

27.

Samet JM, Tal TL (2010) Toxicological disruption of signaling homeostasis: tyrosine phosphatases as targets. Annu Rev Pharmacol Toxicol 50:215–235PubMedCrossRef

28.

Dube N, Tremblay ML (2005) Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer. Biochim Biophys Acta 1754(1–2):108–117PubMedCrossRef

29.

Lees CW, Barrett JC, Parkes M, Satsangi J (2011) New IBD genetics: common pathways with other diseases. Gut 60(12):1739–1753PubMedCrossRef

30.

Scharl M, Paul G, Weber A et al (2009) Protection of epithelial barrier function by the Crohn’s disease associated gene protein tyrosine phosphatase n2. Gastroenterology 137(6):2030–2040PubMedCentralPubMedCrossRef

31.

Scharl M, Mwinyi J, Fischbeck A et al (2012) Crohn’s disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. Inflamm Bowel Dis 18(5):900–912PubMedCrossRef

32.

Doody KM, Bourdeau A, Tremblay ML (2009) T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model and implications in human disease. Immunol Rev 228(1):325–341PubMedCrossRef

33.

Hassan SW, Doody KM, Hardy S, Uetani N, Cournoyer D, Tremblay ML (2010) Increased susceptibility to dextran sulfate sodium induced colitis in the T cell protein tyrosine phosphatase heterozygous mouse. PLoS One 5(1):e8868PubMedCentralPubMedCrossRef

34.

Yamamoto T, Sekine Y, Kashima K et al (2002) The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation. Biochem Biophys Res Commun 297(4):811–817PubMedCrossRef

35.

Vanden Berghe W, Vermeulen L, De WG, De BK, Boone E, Haegeman G (2000) Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 60(8):1185–1195PubMedCrossRef

36.

Chen G, Shaw MH, Kim YG, Nunez G (2009) NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 4:365–398PubMedCrossRef

37.

Zhu S, Qian Y (2012) IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 122(11):487–511CrossRef

38.

Hume DA, MacDonald KP (2012) Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119(8):1810–1820PubMedCrossRef

39.

Ramos PS, Criswell LA, Moser KL et al (2011) A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap. PLoS Genet 7(12):e1002406PubMedCentralPubMedCrossRef

40.

Orozco G, Eyre S, Hinks A et al (2011) Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 70(3):463–468PubMedCentralPubMedCrossRef

41.

Gateva V, Sandling JK, Hom G et al (2009) A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41(11):1228–1233PubMedCentralPubMedCrossRef

42.

Cunninghame Graham DS, Morris DL, Bhangale TR et al (2011) Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet 7(10):e1002341PubMedCentralPubMedCrossRef

43.

Budarf ML, Goyette P, Boucher G et al (2011) A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles. Genes Immun 12(1):51–58PubMedCrossRef

44.

Oxer DS, Godoy LC, Borba E et al (2011) PPARgamma expression is increased in systemic lupus erythematosus patients and represses CD40/CD40L signaling pathway. Lupus 20(6):575–587PubMedCrossRef

45.

Savitsky D, Tamura T, Yanai H, Taniguchi T (2010) Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother 59(4):489–510PubMedCrossRef

46.

Tada Y, Kondo S, Aoki S et al (2011) Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice. Arthritis Rheum 63(3):738–748PubMedCrossRef

47.

Panchanathan R, Liu H, Liu H et al (2012) Distinct regulation of murine lupus susceptibility genes by the IRF5/Blimp-1 axis. J Immunol 188(1):270–278PubMedCentralPubMedCrossRef

48.

Feng D, Stone RC, Eloranta ML et al (2010) Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum 62(2):562–573PubMedCentralPubMed

49.

Yasuda K, Richez C, Maciaszek JW et al (2007) Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol 178(11):6876–6885PubMedCrossRef

50.

Yanai H, Chen HM, Inuzuka T et al (2007) Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci U S A 104(9):3402–3407PubMedCentralPubMedCrossRef

51.

Stanford SM, Mustelin TM, Bottini N (2010) Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases. Semin Immunopathol 32(2):127–136PubMedCentralPubMedCrossRef

52.

Burn GL, Svensson L, Sanchez-Blanco C, Saini M, Cope AP (2011) Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Lett 585(23):3689–3698PubMedCrossRef

53.

Siasos G, Tousoulis D, Kioufis S et al (2012) Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases. Curr Top Med Chem 12(10):1132–1148PubMedCrossRef

54.

Dai C, Deng Y, Quinlan A, Gaskin F, Tsao BP, Fu SM (2014) Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr Opin Immunol 31C:87–96CrossRef

55.

Fu Q, Zhao J, Qian X et al (2011) Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum 63(3):749–754PubMedCentralPubMedCrossRef

Titel: Genetics of serum concentration of IL-6 and TNFα in systemic lupus erythematosus and rheumatoid arthritis: a candidate gene analysis
verfasst von: Joseph F. Solus
Cecilia P. Chung
Annette Oeser
Chun Li
Young Hee Rho
Kevin M. Bradley
Vivian K. Kawai
Jeffrey R. Smith
C. Michael Stein
Publikationsdatum: 01.08.2015
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 8/2015
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-015-2881-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2015

Early systemic sclerosis—opportunities for treatment

Peripartum changes of the sacroiliac joints on MRI: increasing mechanical load correlating with signs of edema and inflammation kindling spondyloarthropathy in the genetically prone

The association of comorbid conditions with patient-reported outcomes in Veterans with hip and knee osteoarthritis

Prevalence of atherosclerosis in patients with inactive rheumatoid arthritis

Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists